Clinical Trial Update: Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial update for pembrolizumab in metastatic HER2-negative breast cancer patients with APOBEC3B mutation; the study status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Malaya | Conditions: HER2-Negative Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING